Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob M. Sands discuss the rationale for incorporating the various anti-HER2 therapies in the clinic, and with the use of 3D animation address the emergence of anti-HER2 treatment resistance and novel approaches to overcome that resistance.